

SmartPA Criteria Proposal

Drug/Drug Class:	Opioid Emergency Reversal Agents PDL Edit
First Implementation Date:	April 6, 2017
Proposed Date:	December 15, 2022
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Naloxone is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. In Missouri in 2021, nearly 1 out of 47 deaths statewide were attributed to an opioid-involved overdose. All products reviewed within this PDL class will be available without restriction as “preferred” products for MO HealthNet participants at risk of harm from an opiate overdose. Pharmacists in Missouri are able to dispense naloxone according to protocol upon request or upon presentation of a valid prescription. A statewide Standing Order issued by the Missouri Department of Health and Senior Services is available at <https://pr.mo.gov/boards/pharmacy/NaloxoneStandingOrder.pdf>.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> Kloxxado™ Naloxone Inj Narcan® NS Zimhi™ 	<ul style="list-style-type: none"> Naloxone 4 mg NS (gen Narcan)

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Opioid Emergency Reversal Agents
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Claim is for a preferred product

Denial Criteria

- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List Edit)
Rule Type: PDL

Default Approval Period

3 months

References

- Evidence-Based Medicine and Fiscal Analysis: "Therapeutic Class Review: CENTRAL NERVOUS SYSTEM: Analgesics, Opiate Emergency Reversal Agents", Gainwell Technologies; Last updated October 23, 2022.
- Evidence-Based Medicine Analysis: "Opiate Emergency Reversal Agents", UMKC-DIC; September 2022.
- Missouri Department of Health and Senior Services. Missouri Opioids Information. <http://health.mo.gov/data/opioids/> . Website accessed November 10, 2022.
- Missouri Opioid State Target Response (STR) Project. <https://www.nomodeaths.org/>. Accessed November 10, 2022.
- USPDI, Micromedex; 2022.
- Drug Facts and Comparisons On-line; 2022.